The combination of clinical factors (age, BMI, CKD and diabetes) with CYP2C19 genetic variants likely captures both the pharmacokinetic and pharmacodynamic aspects of antiplatelet response, advancing the application of precision medicine in cardiovascular disease management. Here, CYP2C19 is linked to chronic kidney disease.